BRIDGEWATER, NJ / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therape ...

Healthcare stock Theralase Technologies (TSXV:TLT) recently discovered that its lead drug candidate, Ruvidar, has the potential to inhibit deubiquitinating enzymes, which are linked to certain cancers ...

Nature Communications Medicine has published the first peer reviewed, real-world analysis of U.S. patients treated with Lenire, the only FDA approved tinnitus treatment device of its kind.

Dimerix (ASX:DXB) confirms primary endpoint for full marketing approval in the US for its DMX-200 treatment in (FSGS). ...

Report Ocean has published a new report on the Saudi Arabia Implantable Drug Delivery Devices market, delivering an extensive analysis of key factors such as market restraints, dr ...

After a failed experiment with legal leniency, Oregon’s liberal stronghold tries to chart a path out of the fentanyl crisis.

U.S. Health Secretary Robert F. Kennedy Jr. told a personal story of his heroin addiction, spiritual awakening and recovery ...

Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

You have probably heard the term “ultra-processed food.” What does that mean? Unprocessed food probably requires little explanation. For example, ...

Unlike current antimicrobial coatings, the new formula locks the active ingredient in place, remaining effective without ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.